Bausch & Lomb and Galapagos sign agreement to collaborate on ophthalmic disease research
"The agreement provides access to a group of compounds that may have excellent development candidate potential," said Praveen Tyle, Ph.D., Chief Scientific Officer, Bausch & Lomb. "The small molecule compounds under evaluation have very attractive in vitro and in vivo profiles. Our intent is to develop these compounds as unique therapies, tapping our research expertise in ophthalmic diseases."
Bausch & Lomb is responsible for the preclinical and clinical development of the select compounds for use in ophthalmic diseases. Under the terms of the collaboration, Galapagos will receive an upfront payment of US$400,000 and may receive research funding to support Bausch & Lomb's further development of the compounds for ophthalmic uses, plus future milestone payments.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.